Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The investigators propose a randomized double-blind 8 week treatment trial of intranasal
oxytocin (IN-OXT) vs. placebo in 24 subjects aged 5 to 18 years with PWS in order to assess
IN-OXT's affect on (1) Eating behaviors (2) Repetitive and disruptive behaviors and (3)
Salivary OXT levels.